<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22839504</article-id><article-id pub-id-type="pmc">3580724</article-id><article-id pub-id-type="publisher-id">cc11444</article-id><article-id pub-id-type="doi">10.1186/cc11444</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effects of endotoxin on lactate metabolism in humans</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Michaeli</surname><given-names>Burkhard</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Burkhard.Michaeli@chuv.ch</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Martinez</surname><given-names>Alexandre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>freevision@gmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Revelly</surname><given-names>Jean-Pierre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Jean-Pierre.Revelly@chuv.ch</email></contrib><contrib contrib-type="author" deceased="yes" id="A4"><name><surname>Cayeux</surname><given-names>Marie-Christine</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mccayeux@bluewin.ch</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Chioléro</surname><given-names>René L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>chiolero@bluewin.ch</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Tappy</surname><given-names>Luc</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Luc.Tappy@unil.ch</email></contrib><contrib contrib-type="author" corresp="yes" id="A7"><name><surname>Berger</surname><given-names>Mette M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Mette.Berger@chuv.ch</email></contrib></contrib-group><aff id="I1"><label>1</label>Service of Adult Intensive Care, Lausanne University Hospital (CHUV), Rue du Bugnon 46, Lausanne 1011, Switzerland</aff><aff id="I2"><label>2</label>Department of Physiology, University of Lausanne, School of Biology and Medicine, Rue du Bugnon 7, Lausanne 1011, Switzerland</aff><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>27</day><month>7</month><year>2012</year></pub-date><volume>16</volume><issue>4</issue><fpage>R139</fpage><lpage>R139</lpage><history><date date-type="received"><day>29</day><month>2</month><year>2012</year></date><date date-type="rev-recd"><day>22</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Copyright ©2012 Michaeli et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Michaeli et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/16/4/R139"></self-uri><abstract><sec><title><offsets xml_i="4054" xml_f="4066" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="4077" xml_f="4600" txt_i="24" txt_f="547">Hyperlactatemia represents one prominent component of the metabolic response to sepsis. In critically ill patients, hyperlactatemia is related to the severity of the underlying condition. Both an increased production and a decreased utilization and clearance might be involved in this process, but their relative contribution remains unknown. The present study aimed at assessing systemic and muscle lactate production and systemic lactate clearance in healthy human volunteers, using intravenous endotoxin (LPS) challenge.</offsets></p></sec><sec><title><offsets xml_i="4622" xml_f="4629" txt_i="549" txt_f="556">Methods</offsets></title><p><offsets xml_i="4640" xml_f="5229" txt_i="557" txt_f="1146">Fourteen healthy male volunteers were enrolled in 2 consecutive studies (n = 6 in trial 1 and n = 8 in trial 2). Each subject took part in one of two investigation days (LPS-day with endotoxin injection and placebo-day with saline injection) separated by one week at least and in a random order. In trial 1, their muscle lactate metabolism was monitored using microdialysis. In trial 2, their systemic lactate metabolism was monitored by means of a constant infusion of exogenous lactate. Energy metabolism was monitored by indirect calorimetry and glucose kinetics was measured with 6,6-H</offsets><sub><offsets xml_i="5234" xml_f="5236" txt_i="1146" txt_f="1148">2 </offsets></sub><offsets xml_i="5242" xml_f="5250" txt_i="1148" txt_f="1156">glucose.</offsets></p></sec><sec><title><offsets xml_i="5272" xml_f="5279" txt_i="1158" txt_f="1165">Results</offsets></title><p><offsets xml_i="5290" xml_f="5736" txt_i="1166" txt_f="1609">In both trials, LPS increased energy expenditure (p = 0.011), lipid oxidation (p&lt;0.0001), and plasma lactate concentration (p = 0.016). In trial 1, lactate concentration in the muscle microdialysate was higher than in blood, indicating lactate production by muscles. This was, however, similar with and without LPS. In trial 2, calculated systemic lactate production increased after LPS (p = 0.031), while lactate clearance remained unchanged.</offsets></p></sec><sec><title><offsets xml_i="5758" xml_f="5769" txt_i="1611" txt_f="1622">Conclusions</offsets></title><p><offsets xml_i="5780" xml_f="5992" txt_i="1623" txt_f="1835">LPS administration increases lactatemia by increasing lactate production rather than by decreasing lactate clearance. Muscle is, however, unlikely to be a major contributor to this increase in lactate production.</offsets></p></sec><sec><title><offsets xml_i="6014" xml_f="6032" txt_i="1837" txt_f="1855">Trial registration</offsets></title><p><offsets xml_i="6043" xml_f="6062" txt_i="1856" txt_f="1875">ClinicalTrials.gov </offsets><ext-link ext-link-type="uri" xlink:href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=NCT01647997"><offsets xml_i="6175" xml_f="6186" txt_i="1875" txt_f="1886">NCT01647997</offsets></ext-link></p></sec></abstract></article-meta><notes><p>See related commentary by Gibot, <ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/16/5/151">http://ccforum.com/content/16/5/151</ext-link></p></notes></front><body><sec><title><offsets xml_i="6439" xml_f="6451" txt_i="1895" txt_f="1907">Introduction</offsets></title><p><offsets xml_i="6462" xml_f="6608" txt_i="1908" txt_f="2054">Sepsis and inflammation elicit a whole set of neuroendocrine, metabolic, and systemic responses that belong to the organism's defense mechanisms [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6639" xml_f="6640" txt_i="2054" txt_f="2055">1</offsets></xref><offsets xml_i="6647" xml_f="6648" txt_i="2055" txt_f="2056">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6679" xml_f="6680" txt_i="2056" txt_f="2057">2</offsets></xref><offsets xml_i="6687" xml_f="6767" txt_i="2057" txt_f="2137">]. However, when excessive, these responses may also exert deleterious effects [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6798" xml_f="6799" txt_i="2137" txt_f="2138">3</offsets></xref><offsets xml_i="6806" xml_f="6939" txt_i="2138" txt_f="2271">]. Hyperlactatemia represents one prominent component of the metabolic stress response but shows marked inter-individual variations [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6970" xml_f="6971" txt_i="2271" txt_f="2272">4</offsets></xref><offsets xml_i="6978" xml_f="6979" txt_i="2272" txt_f="2273">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7010" xml_f="7011" txt_i="2273" txt_f="2274">6</offsets></xref><offsets xml_i="7018" xml_f="7170" txt_i="2274" txt_f="2426">]. In critically ill patients, hyperlactatemia has been shown to be related to both the severity of the underlying condition and in-hospital mortality [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7201" xml_f="7202" txt_i="2426" txt_f="2427">7</offsets></xref><offsets xml_i="7209" xml_f="7211" txt_i="2427" txt_f="2429">].</offsets></p><p><offsets xml_i="7218" xml_f="7398" txt_i="2430" txt_f="2610">The mechanisms underlying the development of hyperlactatemia in sepsis remain poorly understood: increased production or decreased clearance or a combination of both are possible [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7429" xml_f="7430" txt_i="2610" txt_f="2611">8</offsets></xref><offsets xml_i="7437" xml_f="7567" txt_i="2611" txt_f="2741">]. A rise in plasma lactate concentrations may result from a decreased lactate clearance secondary to low tissue oxygen delivery [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7598" xml_f="7599" txt_i="2741" txt_f="2742">9</offsets></xref><offsets xml_i="7606" xml_f="7607" txt_i="2742" txt_f="2743">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="7639" xml_f="7641" txt_i="2743" txt_f="2745">10</offsets></xref><offsets xml_i="7648" xml_f="7831" txt_i="2745" txt_f="2928">] or from an increase in lactate production secondary to anaerobic metabolism in under-perfused tissues or to stimulation of aerobic glycolysis in response to inflammatory mediators [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="7863" xml_f="7865" txt_i="2928" txt_f="2930">11</offsets></xref><offsets xml_i="7872" xml_f="7873" txt_i="2930" txt_f="2931">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7905" xml_f="7907" txt_i="2931" txt_f="2933">12</offsets></xref><offsets xml_i="7914" xml_f="8073" txt_i="2933" txt_f="3092">]. The relative importance of these two processes, as well as the major tissues where lactate metabolism is altered by sepsis, remains incompletely understood.</offsets></p><p><offsets xml_i="8080" xml_f="8283" txt_i="3093" txt_f="3296">The impact of inflammation on the different metabolic pathways can be investigated by using a reproducible model of acute inflammation, consisting of endotoxin administration (lipopolysaccharide = LPS) [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="8315" xml_f="8317" txt_i="3296" txt_f="3298">13</offsets></xref><offsets xml_i="8324" xml_f="8543" txt_i="3298" txt_f="3517">], which closely mimics some important aspects of sepsis and has the advantage of being short-lived. LPS elicits the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) and interleukins (ILs) [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8575" xml_f="8577" txt_i="3517" txt_f="3519">14</offsets></xref><offsets xml_i="8584" xml_f="8585" txt_i="3519" txt_f="3520">-</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8617" xml_f="8619" txt_i="3520" txt_f="3522">17</offsets></xref><offsets xml_i="8626" xml_f="8696" txt_i="3522" txt_f="3592">] and reproduces most of the neuroendocrine and metabolic alterations.</offsets></p><p><offsets xml_i="8703" xml_f="9335" txt_i="3593" txt_f="4225">The present study aimed at investigating the relationship between inflammation and lactate metabolism and comparing local muscle responses and systemic metabolism. The objectives were to investigate the effect of endotoxin on the muscle lactate production in a first set of studies (trial 1) and on whole-body endogenous lactate production and lactate clearance in a second set of studies (trial 2). Since lactate is a major gluconeogenic precursor, an additional aim of this study was to evaluate the effects of an increased lactate supply on glucose production and glycemic control during endotoxin-induced sepsis-like conditions.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="9386" xml_f="9407" txt_i="4227" txt_f="4248">Materials and methods</offsets></title><sec><title><offsets xml_i="9427" xml_f="9448" txt_i="4249" txt_f="4270">Subjects and protocol</offsets></title><p><offsets xml_i="9459" xml_f="10215" txt_i="4271" txt_f="5027">The study was conducted with institutional ethics committee approval (Commission cantonale (VD) d'éthique de la recherche sur l'être humain) and individual signed informed consent. Fourteen healthy male volunteers were enrolled, and each subject took part in one of two consecutive parts of this study. The subjects were studied in a random order and on two occasions separated by at least one week: once with endotoxin administration (LPS day) and once with placebo (placebo day). Inclusion criteria were age of between 18 and 30 years and body mass index (BMI) of between 19.5 and 25. Exclusion criteria were family history of metabolic or endocrine disease, smoking, alcohol consumption, and current medication. The study design is summarized in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="10245" xml_f="10246" txt_i="5027" txt_f="5028">1</offsets></xref><offsets xml_i="10253" xml_f="10254" txt_i="5028" txt_f="5029">.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="10295" xml_f="10303" txt_i="5030" txt_f="5038">Figure 1</offsets></label><caption><p><bold><offsets xml_i="10329" xml_f="10341" txt_i="5038" txt_f="5050">Study design</offsets></bold><offsets xml_i="10348" xml_f="10374" txt_i="5050" txt_f="5076">. LPS, lipopolysaccharide.</offsets></p></caption><graphic xlink:href="cc11444-1"></graphic></fig><p><offsets xml_i="10439" xml_f="10935" txt_i="5077" txt_f="5573">The subjects came to the metabolic laboratory at 7 a.m. after an overnight fast. Upon arrival, they were requested to void, and the urine was discarded. Thereafter, they remained supine quietly in a bed for the next 10 hours. An antecubital vein was cannulated for labeled tracer infusion. A dorsal hand vein of the opposite arm was cannulated to collected blood samples. This hand was placed in a thermostabilized box, which was heated at 50°C to achieve partial arterialization of venous blood.</offsets></p><p><offsets xml_i="10942" xml_f="11149" txt_i="5574" txt_f="5781">After stabilization and tracer equilibration, endotoxin (LPS day: 2 ng/kg; US Pharmacopeial Convention, Rockville, MD, USA) or placebo (placebo day: NaCl 0.9%) was administrated as an intravenous bolus (T0).</offsets></p><p><offsets xml_i="11156" xml_f="11480" txt_i="5782" txt_f="6106">Blood samples were collected at regular intervals up to 390 minutes later (T390) to determine glucose, triglycerides, free fatty acids (FFAs), insulin, glucagon, lactate, cortisol, adrenocorticotropine (ACTH), norepinephrine, epinephrine, TNF-α, IL-6, and C-reactive protein (CRP) concentrations and to determine plasma 6,6 </offsets><sup><offsets xml_i="11485" xml_f="11486" txt_i="6106" txt_f="6107">2</offsets></sup><offsets xml_i="11492" xml_f="11493" txt_i="6107" txt_f="6108">H</offsets><sub><offsets xml_i="11498" xml_f="11500" txt_i="6108" txt_f="6110">2 </offsets></sub><offsets xml_i="11506" xml_f="11692" txt_i="6110" txt_f="6296">glucose isotopic enrichment. Blood samples were collected into heparinized tubes and centrifuged to separate plasma. Plasma was stored at -20°C (-80°C for catecholamines) until analysis.</offsets></p><p><offsets xml_i="11699" xml_f="11724" txt_i="6297" txt_f="6322">Oxygen consumption and CO</offsets><sub><offsets xml_i="11729" xml_f="11731" txt_i="6322" txt_f="6324">2 </offsets></sub><offsets xml_i="11737" xml_f="11853" txt_i="6324" txt_f="6440">production measured by indirect calorimetry (by means of open-circuit indirect calorimetry as described previously [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="11885" xml_f="11887" txt_i="6440" txt_f="6442">18</offsets></xref><offsets xml_i="11894" xml_f="11944" txt_i="6442" txt_f="6492">]) were used to determine the energy expenditure [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="11976" xml_f="11978" txt_i="6492" txt_f="6494">19</offsets></xref><offsets xml_i="11985" xml_f="12435" txt_i="6494" txt_f="6944">]. Urine was sampled from spontaneous voiding throughout the study to assess the urinary urea nitrogen excretion. Heart rate, rectal temperature (Hellige; Servomed, Cairo, Egypt), arterial pressure, cardiac output by bioimpedance (NCCOM3 cardiodynamic monitor; BoMed, Irvine, CA, USA), and oxygen saturation (Biox 3740 Pulse oximeter; Ohmeda, now part of GE Healthcare, Little Chalfont, Buckinghamshire, UK) were monitored throughout the experiments.</offsets></p><sec><title><offsets xml_i="12451" xml_f="12484" txt_i="6945" txt_f="6978">Glucose turnover (trials 1 and 2)</offsets></title><p><offsets xml_i="12495" xml_f="12625" txt_i="6979" txt_f="7109">After blood sampling for determination of basal glucose isotope enrichment and basal lactate, a primed continuous infusion of 6,6 </offsets><sup><offsets xml_i="12630" xml_f="12631" txt_i="7109" txt_f="7110">2</offsets></sup><offsets xml_i="12637" xml_f="12638" txt_i="7110" txt_f="7111">H</offsets><sub><offsets xml_i="12643" xml_f="12645" txt_i="7111" txt_f="7113">2 </offsets></sub><offsets xml_i="12651" xml_f="12865" txt_i="7113" txt_f="7327">glucose (Cambridge Isotope Laboratory, Cambridge, MA, USA; prime 3 mg/kg per minute, continuous 30 μg/kg per minute) was infused from T180 (180 minutes before intravenous endotoxin or placebo) throughout the study.</offsets></p></sec><sec><title><offsets xml_i="12887" xml_f="12910" txt_i="7329" txt_f="7352">Microdialysis (trial 1)</offsets></title><p><offsets xml_i="12921" xml_f="13107" txt_i="7353" txt_f="7539">One microdialysis probe (CMA; Carnegie Medicine, Stockholm, Sweden) was inserted into the muscle vastus lateralis of one thigh and was infused with a Ringer solution containing 1 mmol/L </offsets><sup><offsets xml_i="13112" xml_f="13114" txt_i="7539" txt_f="7541">13</offsets></sup><offsets xml_i="13120" xml_f="13121" txt_i="7541" txt_f="7542">C</offsets><sub><offsets xml_i="13126" xml_f="13128" txt_i="7542" txt_f="7544">3 </offsets></sub><offsets xml_i="13134" xml_f="13474" txt_i="7544" txt_f="7884">lactate (Cambridge Isotope Laboratory) at a rate of 0.3 μL per minute throughout the experiment. The cutoff of the microdialysis membrane was 30 kDa. Microdialysates were collected every hour to evaluate interstitial muscle lactate concentrations. The dialysate was collected at 60-minute intervals for measurement of dialysate lactate and </offsets><sup><offsets xml_i="13479" xml_f="13481" txt_i="7884" txt_f="7886">13</offsets></sup><offsets xml_i="13487" xml_f="13512" txt_i="7886" txt_f="7911">C lactate concentrations.</offsets></p></sec><sec><title><offsets xml_i="13534" xml_f="13561" txt_i="7913" txt_f="7940">Lactate clearance (trial 2)</offsets></title><p><offsets xml_i="13572" xml_f="13731" txt_i="7941" txt_f="8100">Changes in lactate clearance and production elicited by endotoxin were evaluated by means of a continuous exogenous lactate infusion, as previously described [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="13763" xml_f="13765" txt_i="8100" txt_f="8102">20</offsets></xref><offsets xml_i="13772" xml_f="13982" txt_i="8102" txt_f="8312">]. Lactate (10 μmol/kg per minute) was infused from T90 until T270. Systemic lactate kinetics (lactate clearance and endogenous production) were assessed by means of a modified method of Connor and colleagues [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="14014" xml_f="14016" txt_i="8312" txt_f="8314">21</offsets></xref><offsets xml_i="14023" xml_f="14025" txt_i="8314" txt_f="8316">].</offsets></p></sec></sec><sec><title><offsets xml_i="14053" xml_f="14074" txt_i="8319" txt_f="8340">Analytical procedures</offsets></title><sec><title><offsets xml_i="14094" xml_f="14112" txt_i="8341" txt_f="8359">Substrate analysis</offsets></title><p><offsets xml_i="14123" xml_f="15315" txt_i="8360" txt_f="9552">Plasma glucose concentrations were measured enzymatically by using a YSI 2300 Stat Plus (YSI Incorporated, Yellow Springs, OH, USA), and plasma FFA concentrations were measured with a colorimetric method and a kit from Wako Chemicals GmbH (Neuss, Germany). Triglyceride levels were analyzed enzymatically by using the PAP 150 test (bioMérieux, Marcy l'Etoile, France). The urine nitrogen excretion rate was determined by means of the micro-Kjeldahl method. Concentrations of ACTH were determined with a chemiluminescence assay kit (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). Concentrations of insulin (kit from Adaltis, Casalecchio di Reno, Italy), cortisol (kit from Diagnostic Products Corporation, Los Angeles, CA, USA), and glucagon (kit from Linco Research, St. Charles, MO, USA) were determined by radioimmunoassay. Plasma concentrations of bioactive IL-6 and TNF-α were determined by using radioimmunoassay. CRP was analyzed by turbidimetry on a Hitachi 917 (Roche, Basel, Switzerland) by using reactants produced by Dako Schweiz AG (Baar, Switzerland). Plasma catecholamines were determined by high-performance liquid chromatography with electrochemical detection [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="15347" xml_f="15349" txt_i="9552" txt_f="9554">22</offsets></xref><offsets xml_i="15356" xml_f="15370" txt_i="9554" txt_f="9568">]. Plasma 6,6 </offsets><sup><offsets xml_i="15375" xml_f="15376" txt_i="9568" txt_f="9569">2</offsets></sup><offsets xml_i="15382" xml_f="15383" txt_i="9569" txt_f="9570">H</offsets><sub><offsets xml_i="15388" xml_f="15390" txt_i="9570" txt_f="9572">2 </offsets></sub><offsets xml_i="15396" xml_f="15736" txt_i="9572" txt_f="9912">glucose isotopic enrichments were determined on deproteinized samples partially purified over sequential cation-anion exchange resins (AG 1-X8 and AG 50W-X8; Bio-Rad Laboratories, Richmond, CA, USA). For glucose measurements, pentaacetyl glucose was analyzed with gas chromatography-mass spectrometry (Hewlett-Packard, Palo Alto, CA, USA) [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="15768" xml_f="15770" txt_i="9912" txt_f="9914">23</offsets></xref><offsets xml_i="15777" xml_f="15872" txt_i="9914" txt_f="10009">]. Dialysate lactate concentration was measured by using a CMA microdialysis analyzer 600. The </offsets><sup><offsets xml_i="15877" xml_f="15879" txt_i="10009" txt_f="10011">13</offsets></sup><offsets xml_i="15885" xml_f="15988" txt_i="10011" txt_f="10114">C lactate enrichment was measurement by gas chromatography-mass spectrometer, as previously described [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="16020" xml_f="16022" txt_i="10114" txt_f="10116">24</offsets></xref><offsets xml_i="16029" xml_f="16031" txt_i="10116" txt_f="10118">].</offsets></p></sec><sec><title><offsets xml_i="16053" xml_f="16065" txt_i="10120" txt_f="10132">Calculations</offsets></title><p><offsets xml_i="16076" xml_f="16162" txt_i="10133" txt_f="10219">Glucose rates of appearance and utilization (trials 1 and 2) were calculated from 6,6 </offsets><sup><offsets xml_i="16167" xml_f="16168" txt_i="10219" txt_f="10220">2</offsets></sup><offsets xml_i="16174" xml_f="16175" txt_i="10220" txt_f="10221">H</offsets><sub><offsets xml_i="16180" xml_f="16182" txt_i="10221" txt_f="10223">2 </offsets></sub><offsets xml_i="16188" xml_f="16246" txt_i="10223" txt_f="10281">glucose by using Steele's equations for non-steady state [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="16278" xml_f="16280" txt_i="10281" txt_f="10283">25</offsets></xref><offsets xml_i="16287" xml_f="16472" txt_i="10283" txt_f="10468">]. Substrate oxidation and energy expenditure were calculated from respiratory gas exchanges and urinary urea nitrogen excretion rates by using the equations of Livesey and colleagues [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="16504" xml_f="16506" txt_i="10468" txt_f="10470">26</offsets></xref><offsets xml_i="16513" xml_f="16565" txt_i="10470" txt_f="10522">] corrected for urinary bicarbonate excretion rate [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="16597" xml_f="16599" txt_i="10522" txt_f="10524">27</offsets></xref><offsets xml_i="16606" xml_f="16608" txt_i="10524" txt_f="10526">].</offsets></p><p><offsets xml_i="16615" xml_f="17143" txt_i="10527" txt_f="11055">For microdialysis measurements (trial 1), tissue substrate production is reflected by a positive gradient of concentration between the dialysate and the systemic circulation. This gradient was calculated as the difference of dialysate concentrations and systemic plasma concentrations, and a near-complete substrate recovery at the low flow rate (0.3 μL per minute) used in these experiments was assumed. Interstitial lactate concentrations were calculated by dividing dialysate lactate concentration by the recovery of infused </offsets><sup><offsets xml_i="17148" xml_f="17150" txt_i="11055" txt_f="11057">13</offsets></sup><offsets xml_i="17156" xml_f="17181" txt_i="11057" txt_f="11082">C lactate, as described [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="17213" xml_f="17215" txt_i="11082" txt_f="11084">24</offsets></xref><offsets xml_i="17222" xml_f="17223" txt_i="11084" txt_f="11085">,</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="17255" xml_f="17257" txt_i="11085" txt_f="11087">28</offsets></xref><offsets xml_i="17264" xml_f="17266" txt_i="11087" txt_f="11089">].</offsets></p><p><offsets xml_i="17273" xml_f="17936" txt_i="11090" txt_f="11753">Lactate clearance (trial 2) was calculated as the quotient of exogenous lactate infusion rate and the plasma lactate difference (Δ lactate) induced by lactate infusion. Delta lactate was calculated from basal concentration (mean from T-150 to T-120) and plateau concentrations (mean from T-30 to T0) due to the start of lactate infusion as well as from plateau (mean from T240 to T270) and the fall to final lactate levels (mean from T360 to T390) due to the stop of lactate infusion. This procedure assumes that lactate concentrations do not vary significantly 5 hours after LPS administration. This has been documented in an earlier study performed in our lab [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="17968" xml_f="17970" txt_i="11753" txt_f="11755">29</offsets></xref><offsets xml_i="17977" xml_f="17979" txt_i="11755" txt_f="11757">].</offsets></p></sec><sec><title><offsets xml_i="18001" xml_f="18021" txt_i="11759" txt_f="11779">Statistical analysis</offsets></title><p><offsets xml_i="18032" xml_f="18274" txt_i="11780" txt_f="12022">Data were analyzed by using one-way or two-way analysis of variance (ANOVA) as appropriate. To determine whether lactate perfusion has an influence on the inflammatory response, two-way ANOVA was used to compare placebo groups of each trial. </offsets><italic><offsets xml_i="18282" xml_f="18291" txt_i="12022" txt_f="12031">Post hoc </offsets></italic><offsets xml_i="18300" xml_f="18387" txt_i="12031" txt_f="12118">analysis (Tukey test) was used in the presence of statistically significant changes. A </offsets><italic><offsets xml_i="18395" xml_f="18397" txt_i="12118" txt_f="12120">P </offsets></italic><offsets xml_i="18406" xml_f="18531" txt_i="12120" txt_f="12245">value of less than 0.05 was considered significant. The statistical package was JMP 8.0 (SAS Institute, Inc., Cary, NC, USA).</offsets></p></sec></sec></sec><sec sec-type="results"><title><offsets xml_i="18584" xml_f="18591" txt_i="12249" txt_f="12256">Results</offsets></title><p><offsets xml_i="18602" xml_f="18827" txt_i="12257" txt_f="12482">Characteristics of subjects were similar in the two trials (trial 1: n = 6; trial 2: n = 8): mean ages of 27.1 ± 2.4 and 26.7 ± 3.3 years, mean body weights of 74.8 ± 3.4 kg and 75.0 ± 6.9 kg, and mean BMIs of 24.0 ± 2.2 kg/m</offsets><sup><offsets xml_i="18832" xml_f="18834" txt_i="12482" txt_f="12484">2 </offsets></sup><offsets xml_i="18840" xml_f="18859" txt_i="12484" txt_f="12503">and 23.9 ± 1.8 kg/m</offsets><sup><offsets xml_i="18864" xml_f="18865" txt_i="12503" txt_f="12504">2</offsets></sup><offsets xml_i="18871" xml_f="18886" txt_i="12504" txt_f="12519">, respectively.</offsets></p><sec><title><offsets xml_i="18902" xml_f="18955" txt_i="12520" txt_f="12573">General and hemodynamic effects of lipopolysaccharide</offsets></title><p><offsets xml_i="18966" xml_f="19107" txt_i="12574" txt_f="12715">All subjects complained of headache, myalgia, and nausea. After LPS, significant increases in body temperature (mean peak at T240 of +1.7°C; </offsets><italic><offsets xml_i="19115" xml_f="19117" txt_i="12715" txt_f="12717">P </offsets></italic><offsets xml_i="19126" xml_f="19146" txt_i="12717" txt_f="12734">&lt;0.0001) (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19176" xml_f="19177" txt_i="12734" txt_f="12735">2</offsets></xref><offsets xml_i="19184" xml_f="19245" txt_i="12735" txt_f="12796">) and heart rate (mean peak of +38 beats per minute) (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19275" xml_f="19276" txt_i="12796" txt_f="12797">2</offsets></xref><offsets xml_i="19283" xml_f="19425" txt_i="12797" txt_f="12939">) were observed, whereas mean blood pressure did not decrease significantly. Transcutaneous oxygen saturation remained normal in all subjects.</offsets></p><fig id="F2" position="float"><label><offsets xml_i="19466" xml_f="19474" txt_i="12940" txt_f="12948">Figure 2</offsets></label><caption><p><bold><offsets xml_i="19500" xml_f="19581" txt_i="12948" txt_f="13029">Evolution of temperature and energy expenditure during the trial in four sessions</offsets></bold><offsets xml_i="19588" xml_f="19589" txt_i="13029" txt_f="13030">.</offsets></p></caption><graphic xlink:href="cc11444-2"></graphic></fig></sec><sec><title><offsets xml_i="19669" xml_f="19712" txt_i="13032" txt_f="13075">Acute neuroendocrine and cytokine responses</offsets></title><p><offsets xml_i="19723" xml_f="19779" txt_i="13076" txt_f="13132">After endotoxin administration, plasma cortisol (Figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="19809" xml_f="19810" txt_i="13132" txt_f="13133">3</offsets></xref><offsets xml_i="19817" xml_f="19844" txt_i="13133" txt_f="13160">) increased significantly (</offsets><italic><offsets xml_i="19852" xml_f="19854" txt_i="13160" txt_f="13162">P </offsets></italic><offsets xml_i="19863" xml_f="19929" txt_i="13162" txt_f="13225">&lt;0.0001), peaking at T240. TNF-α also increased significantly (</offsets><italic><offsets xml_i="19937" xml_f="19939" txt_i="13225" txt_f="13227">P </offsets></italic><offsets xml_i="19948" xml_f="20362" txt_i="13227" txt_f="13638">&lt;0.0001), peaking at T90, and was followed by a peak of IL-6 secretion between T120 and T150. Compared with trial 1, the increases in plasma IL-6 and cortisol were more sustained in trial 2 after exogenous lactate infusion. The stress hormones epinephrine and norepinephrine only were determined in trial 2 to have peaked at 120 minutes after LPS for norepinephrine and at 240 minutes after LPS for epinephrine.</offsets></p><fig id="F3" position="float"><label><offsets xml_i="20403" xml_f="20411" txt_i="13639" txt_f="13647">Figure 3</offsets></label><caption><p><bold><offsets xml_i="20437" xml_f="20593" txt_i="13647" txt_f="13803">Evolution over time of tumor necrosis factor-alpha (TNF-α), interleukin-6 cortisol, epinephrine, and norepinephrine after lipopolysaccharide (LPS) injection</offsets></bold><offsets xml_i="20600" xml_f="20603" txt_i="13803" txt_f="13806">. *</offsets><italic><offsets xml_i="20611" xml_f="20613" txt_i="13806" txt_f="13808">P </offsets></italic><offsets xml_i="20622" xml_f="20632" txt_i="13808" txt_f="13815">&lt; 0.05.</offsets></p></caption><graphic xlink:href="cc11444-3"></graphic></fig></sec><sec><title><offsets xml_i="20712" xml_f="20729" txt_i="13817" txt_f="13834">Metabolic effects</offsets></title><p><offsets xml_i="20740" xml_f="20817" txt_i="13835" txt_f="13912">Resting energy expenditure increased significantly in response to endotoxin (</offsets><italic><offsets xml_i="20825" xml_f="20827" txt_i="13912" txt_f="13914">P </offsets></italic><offsets xml_i="20836" xml_f="21150" txt_i="13914" txt_f="14228">= 0.011). Glycemia did not differ significantly at baseline. In both protocols, plasma glucose concentrations showed a biphasic response to endotoxin; an initial maximal decline occurred 2 hours after endotoxin administration, and a moderate rebound increase occurred between 3 and 6 hours after endotoxin (Figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="21180" xml_f="21181" txt_i="14228" txt_f="14229">4</offsets></xref><offsets xml_i="21188" xml_f="21335" txt_i="14229" txt_f="14376">). At T360, glycemia was still significantly higher in the endotoxin subjects of trial 2 in comparison with those of trial 1 (106 versus 91 mg/dL; </offsets><italic><offsets xml_i="21343" xml_f="21345" txt_i="14376" txt_f="14378">P </offsets></italic><offsets xml_i="21354" xml_f="21956" txt_i="14378" txt_f="14977">&lt;0.0001). These changes were related to trends toward a reduced endogenous glucose production concomitant with a modest increase in metabolic glucose clearance early after endotoxin over the first hour after endotoxin, followed by an increase in glucose production, which was sustained throughout the remaining observation time. Endotoxin administration also elicited a 70% increase in plasma glucagon (from 64.6 to 107.4 ng/L at T120 in trial 1 and from 62.5 to 108.1 ng/L at T240 in trial 2) and enhanced the progressive increase in plasma FFA observed in placebo studies, as previously reported [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="21988" xml_f="21990" txt_i="14977" txt_f="14979">30</offsets></xref><offsets xml_i="21997" xml_f="21999" txt_i="14979" txt_f="14981">].</offsets></p><fig id="F4" position="float"><label><offsets xml_i="22040" xml_f="22048" txt_i="14982" txt_f="14990">Figure 4</offsets></label><caption><p><bold><offsets xml_i="22074" xml_f="22221" txt_i="14990" txt_f="15137">Glycemia, endogenous glucose production (EGP), and metabolic glucose clearance (MCR) over time without (a) and with (b) exogenous lactate provision</offsets></bold><offsets xml_i="22228" xml_f="22229" txt_i="15137" txt_f="15138">.</offsets></p></caption><graphic xlink:href="cc11444-4"></graphic></fig><p><offsets xml_i="22294" xml_f="22616" txt_i="15139" txt_f="15461">Plasma insulin concentrations were not affected by endotoxin. In trial 1, endotoxin significantly increased energy expenditure, and this increase was sustained over the 6-hour period of observation. A stimulation of lipid oxidation accounted for this increase in energy expenditure whereas glucose oxidation was unchanged.</offsets></p></sec><sec><title><offsets xml_i="22638" xml_f="22656" txt_i="15463" txt_f="15481">Lactate metabolism</offsets></title><p><offsets xml_i="22667" xml_f="22749" txt_i="15482" txt_f="15564">In trial 1, LPS substantially increased the plasma lactate concentrations (Figure </offsets><xref ref-type="fig" rid="F5"><offsets xml_i="22779" xml_f="22780" txt_i="15564" txt_f="15565">5</offsets></xref><offsets xml_i="22787" xml_f="23271" txt_i="15565" txt_f="16049">). Lactate concentrations peaked at T90 and declined progressively thereafter but remained higher than in the control experiment until the end of the observation period. Muscle interstitial lactate concentrations were systematically higher than plasma lactate concentrations, and their increase paralleled that of plasma lactate. The difference between interstitial lactate concentration and plasma lactate concentration (that is, lactate gradient from muscle towards plasma) (Figure </offsets><xref ref-type="fig" rid="F5"><offsets xml_i="23301" xml_f="23302" txt_i="16049" txt_f="16050">5</offsets></xref><offsets xml_i="23309" xml_f="23329" txt_i="16050" txt_f="16070">) remained constant.</offsets></p><fig id="F5" position="float"><label><offsets xml_i="23370" xml_f="23378" txt_i="16071" txt_f="16079">Figure 5</offsets></label><caption><p><bold><offsets xml_i="23404" xml_f="23557" txt_i="16079" txt_f="16232">Plasma lactate and difference between interstitial muscle and plasma lactate concentrations (lactate gradient of muscle to plasma) at various time points</offsets></bold><offsets xml_i="23564" xml_f="23565" txt_i="16232" txt_f="16233">.</offsets></p></caption><graphic xlink:href="cc11444-5"></graphic></fig><p><offsets xml_i="23630" xml_f="23842" txt_i="16234" txt_f="16446">In trial 2, exogenous lactate infusion achieved a steady plasma lactate concentration during the 30-minute period preceding LPS administration and during the third hour following endotoxin administration (Figure </offsets><xref ref-type="fig" rid="F6"><offsets xml_i="23872" xml_f="23873" txt_i="16446" txt_f="16447">6</offsets></xref><offsets xml_i="23880" xml_f="24124" txt_i="16447" txt_f="16691">). At the end of the exogenous infusion, plasma lactate declined rapidly in both LPS and placebo arms but stabilized at slightly higher values after endotoxin. Lactate production and clearance calculated during these periods are shown in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="24156" xml_f="24157" txt_i="16691" txt_f="16692">1</offsets></xref><offsets xml_i="24164" xml_f="24272" txt_i="16692" txt_f="16800">. Lactate production was significantly increased after endotoxin, whereas lactate clearance was not altered.</offsets></p><fig id="F6" position="float"><label><offsets xml_i="24313" xml_f="24321" txt_i="16801" txt_f="16809">Figure 6</offsets></label><caption><p><bold><offsets xml_i="24347" xml_f="24419" txt_i="16809" txt_f="16881">Plasma lactate in trial 2 in control and lipopolysaccharide (LPS) phases</offsets></bold><offsets xml_i="24426" xml_f="24777" txt_i="16881" txt_f="17232">. Delta (Δ) values are the differences between basal lactate concentration and lactate measured during lactate infusion and were used to calculate whole-body lactate clearance. Since basal lactate was altered by LPS infusion, both the pre-LPS and post-LPS lactate concentrations were used as basal values to calculate (Δ1 and Δ2 values, respectively).</offsets></p></caption><graphic xlink:href="cc11444-6"></graphic></fig><table-wrap id="T1" position="float"><label><offsets xml_i="24883" xml_f="24890" txt_i="17233" txt_f="17240">Table 1</offsets></label><caption><p><offsets xml_i="24910" xml_f="24964" txt_i="17240" txt_f="17294">Lactate clearance and endogenous production in trial 2</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="25043" xml_f="25053" txt_i="17295" txt_f="17305">Time point</offsets></th><th align="center"><offsets xml_i="25077" xml_f="25095" txt_i="17305" txt_f="17323">Lactate clearance,</offsets><break></break><offsets xml_i="25110" xml_f="25126" txt_i="17323" txt_f="17339">mL/kg per minute</offsets></th><th align="center"><offsets xml_i="25150" xml_f="25180" txt_i="17339" txt_f="17369">Endogenous lactate production,</offsets><break></break><offsets xml_i="25195" xml_f="25213" txt_i="17369" txt_f="17387">μmol/kg per minute</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="25259" xml_f="25271" txt_i="17387" txt_f="17399">T0 (placebo)</offsets></td><td align="center"><offsets xml_i="25295" xml_f="25305" txt_i="17400" txt_f="17410">12.4 ± 3.6</offsets></td><td align="center"><offsets xml_i="25329" xml_f="25338" txt_i="17411" txt_f="17420">8.8 ± 2.6</offsets></td></tr><tr><td align="left"><offsets xml_i="25369" xml_f="25383" txt_i="17421" txt_f="17435">T270 (placebo)</offsets></td><td align="center"><offsets xml_i="25407" xml_f="25417" txt_i="17436" txt_f="17446">13.8 ± 2.8</offsets></td><td align="center"><offsets xml_i="25441" xml_f="25451" txt_i="17447" txt_f="17457">10.2 ± 2.1</offsets></td></tr><tr><td align="left"><offsets xml_i="25482" xml_f="25490" txt_i="17458" txt_f="17466">T0 (LPS)</offsets></td><td align="center"><offsets xml_i="25514" xml_f="25524" txt_i="17467" txt_f="17477">12.1 ± 2.6</offsets></td><td align="center"><offsets xml_i="25548" xml_f="25557" txt_i="17478" txt_f="17487">8.7 ± 3.0</offsets></td></tr><tr><td align="left"><offsets xml_i="25588" xml_f="25598" txt_i="17488" txt_f="17498">T270 (LPS)</offsets></td><td align="center"><offsets xml_i="25622" xml_f="25632" txt_i="17499" txt_f="17509">14.3 ± 2.2</offsets></td><td align="center"><offsets xml_i="25656" xml_f="25666" txt_i="17510" txt_f="17520">13.9 ± 2.7</offsets><sup><offsets xml_i="25671" xml_f="25672" txt_i="17520" txt_f="17521">a</offsets></sup></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="25724" xml_f="25769" txt_i="17522" txt_f="17567">Data presented as mean ± standard deviation. </offsets><sup><offsets xml_i="25774" xml_f="25775" txt_i="17567" txt_f="17568">a</offsets></sup><italic><offsets xml_i="25789" xml_f="25791" txt_i="17568" txt_f="17570">P </offsets></italic><offsets xml_i="25800" xml_f="25963" txt_i="17570" txt_f="17733">= 0.031: Endogenous lactate production increased significantly in the lipopolysaccharide (LPS) group. T0, time point at 0 minutes; T270, time point at 270 minutes.</offsets></p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title><offsets xml_i="26044" xml_f="26054" txt_i="17736" txt_f="17746">Discussion</offsets></title><p><offsets xml_i="26065" xml_f="26290" txt_i="17747" txt_f="17972">The present study corroborates earlier reports showing that an acute LPS challenge is a suitable model for the investigation of acute neuroendocrine and metabolic alterations elicited by bacterial infection and early sepsis [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="26322" xml_f="26324" txt_i="17972" txt_f="17974">14</offsets></xref><offsets xml_i="26331" xml_f="26332" txt_i="17974" txt_f="17975">-</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="26364" xml_f="26366" txt_i="17975" txt_f="17977">17</offsets></xref><offsets xml_i="26373" xml_f="26374" txt_i="17977" txt_f="17978">,</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="26406" xml_f="26408" txt_i="17978" txt_f="17980">30</offsets></xref><offsets xml_i="26415" xml_f="26674" txt_i="17980" txt_f="18239">]. Several key features of early sepsis - that is, acute transient increases in body temperature and heart rate, increases in plasma cytokines and stress hormone concentrations, a hypermetabolic state, and alterations of glucose homeostasis - were reproduced.</offsets></p><p><offsets xml_i="26681" xml_f="27134" txt_i="18240" txt_f="18693">Administration of endotoxin increased total energy expenditure by about 35%. This increase was totally accounted for by a stimulation of lipid oxidation, whereas carbohydrate oxidation was not altered. This conclusion rests on the observation that, owing to fasting, net carbohydrate oxidation decreased continuously throughout the experiment but was similar in endotoxin and control experiments. Stimulation of lipolysis, presumably in adipose tissue [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="27166" xml_f="27168" txt_i="18693" txt_f="18695">31</offsets></xref><offsets xml_i="27175" xml_f="27327" txt_i="18695" txt_f="18847">], was documented by an accentuated increase in plasma FFA in comparison with control subjects and was most likely operative in fueling lipid oxidation.</offsets></p><p><offsets xml_i="27334" xml_f="28253" txt_i="18848" txt_f="19767">Although endotoxin did not increase net glucose oxidation, it exerted significant effects on glucose homeostasis. In control subjects, a progressive decline in glucose production and glycemia was observed as a result of fasting. In contrast, administration of endotoxin tended to accentuate this drop in glucose production during the first hour but then consistently and continuously increased glucose production. This effect of endotoxin on glucose production is consistent with previous reports in humans and animals in response to administration of endotoxin and TNF-α and accounts for endotoxin-induced hyperglycemia since the metabolic clearance of glucose was essentially unaffected. Several studies have reported that bacterial endotoxin or administration of inflammatory cytokines induces a transient decrease in plasma glucose and an increase in glucose production and glucose utilization in fasted organisms [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="28285" xml_f="28287" txt_i="19767" txt_f="19769">17</offsets></xref><offsets xml_i="28294" xml_f="28491" txt_i="19769" txt_f="19966">]. Our present observations corroborate and extend these observations by showing that the increase in glucose utilization corresponds essentially to a stimulation of non-oxidative glucose disposal.</offsets></p><p><offsets xml_i="28498" xml_f="29941" txt_i="19967" txt_f="21410">As a result of endotoxin administration, plasma lactate concentration increased consistently, peaked after 90 minutes, and progressively decreased thereafter. Plasma lactate, however, remained elevated throughout the 390-minutes observation period. Lactate concentrations in muscle interstitial fluid (trial 1) were significantly higher than plasma concentration throughout the experiment. This, however, was observed both in control experiments and after endotoxin and was not enhanced by endotoxin. This constant positive muscle-to-plasma gradient of lactate suggests that muscle lactate production was not increased by LPS. However, two limitations to the microdialysis technique need to be addressed. First, since muscle simultaneously produces and uses lactate, we cannot discard the hypothesis that both processes were increased to the same extent and hence that muscle lactate turnover was increased. However, if this was the case, it would not increase the net lactate efflux from muscle and therefore it would not participate in whole-body lactate production as measured in the present experiments. Second, an increased muscle lactate production may have resulted in a constant muscle-to-plasma lactate gradient if muscle blood flow had increased in the same proportion. Although this was not measured in our experiments, several reports indicate that muscle blood flow is not increased and may even be decreased after LPS in humans [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="29973" xml_f="29975" txt_i="21410" txt_f="21412">32</offsets></xref><offsets xml_i="29982" xml_f="29994" txt_i="21412" txt_f="21424">] and rats [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="30026" xml_f="30028" txt_i="21424" txt_f="21426">33</offsets></xref><offsets xml_i="30035" xml_f="30066" txt_i="21426" txt_f="21457">] and in patients with sepsis [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="30098" xml_f="30100" txt_i="21457" txt_f="21459">34</offsets></xref><offsets xml_i="30107" xml_f="30376" txt_i="21459" txt_f="21728">]. If muscle blood flow is assumed not to have increased in our experiments, the absence of an increased interstitial muscle-arterial gradient after LPS indicates that skeletal muscle produces lactate in fasting conditions but that this was not stimulated by endotoxin.</offsets></p><p><offsets xml_i="30383" xml_f="30607" txt_i="21729" txt_f="21953">In trial 2, lactate kinetic was assessed by monitoring plasma lactate concentrations during continuous infusion of exogenous lactate. Continuous infusion of lactate is a variant of the bolus lactate administration approach [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="30639" xml_f="30641" txt_i="21953" txt_f="21955">35</offsets></xref><offsets xml_i="30648" xml_f="30649" txt_i="21955" txt_f="21956">-</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="30681" xml_f="30683" txt_i="21956" txt_f="21958">37</offsets></xref><offsets xml_i="30690" xml_f="30738" txt_i="21958" txt_f="22006">], which we have described in detail elsewhere [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="30770" xml_f="30772" txt_i="22006" txt_f="22008">20</offsets></xref><offsets xml_i="30779" xml_f="30959" txt_i="22008" txt_f="22188">], and rests on the assumption that endogenous lactate production is not significantly affected by exogenous lactate, an assumption that is supported by a previous isotopic study [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="30991" xml_f="30993" txt_i="22188" txt_f="22190">38</offsets></xref><offsets xml_i="31000" xml_f="31753" txt_i="22190" txt_f="22943">]. Calculations of lactate clearance and production with such an approach require that plasma lactate concentration not vary markedly over time, and hence such calculations were possible only in basal conditions and during the fourth hour after endotoxin administration. For the latter, however, lactate concentrations tended to decrease over time in the placebo experiment of trial 2, implying that some underestimation of lactate production and overestimation of lactate clearance cannot be excluded. The data obtained from exogenous lactate infusion provide calculation of basal lactate production that were similar in both control and endotoxin experiments and were comparable to values reported in the literature with bolus lactate administration [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="31785" xml_f="31787" txt_i="22943" txt_f="22945">35</offsets></xref><offsets xml_i="31794" xml_f="31795" txt_i="22945" txt_f="22946">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="31827" xml_f="31829" txt_i="22946" txt_f="22948">36</offsets></xref><offsets xml_i="31836" xml_f="32027" txt_i="22948" txt_f="23139">]. During the fourth hour after endotoxin administration, lactate clearance was unchanged, indicating that increased lactate production was responsible for the development of hyperlactatemia.</offsets></p><p><xref ref-type="bibr" rid="B38"><offsets xml_i="32066" xml_f="32068" txt_i="23140" txt_f="23142">38</offsets></xref><offsets xml_i="32075" xml_f="32106" txt_i="23142" txt_f="23173">] and critically ill patients [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="32138" xml_f="32140" txt_i="23173" txt_f="23175">39</offsets></xref><offsets xml_i="32147" xml_f="32420" txt_i="23175" txt_f="23448">]. This apparently surprising observation can be explained by an autoregulation of glucose production. According to this concept, glycemia per se regulates hepatic glucose output whereas acute alterations of gluconeogenesis lead merely to mirror changes in glycogenolysis [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="32452" xml_f="32454" txt_i="23448" txt_f="23450">40</offsets></xref><offsets xml_i="32461" xml_f="33188" txt_i="23450" txt_f="24177">]. Our present observation, by showing that endogenous glucose production is increased even though plasma glucose is higher (a factor that would normally inhibit hepatic glucose output), clearly indicates alterations of hepatic glucose metabolism. However, failure of exogenous lactate to further increase glucose production and glycemia indicates that hepatic glucose production is still efficiently autoregulated after endotoxin. This indicates (a) that increased gluconeogenic precursor availability is not the major factor responsible for an increase in glucose output and (b) that endotoxin administration increases fasting glycemia by resetting autoregulation of hepatic glucose production toward a higher glycemic level.</offsets></p><p><offsets xml_i="33195" xml_f="33324" txt_i="24178" txt_f="24307">It must be emphasized, though, that our subjects had been fasted overnight before the test, and this affects glucose metabolism [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="33356" xml_f="33358" txt_i="24307" txt_f="24309">41</offsets></xref><offsets xml_i="33365" xml_f="33437" txt_i="24309" txt_f="24381">] but also the response to LPS, as in the trial by Fong and colleagues [</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="33469" xml_f="33471" txt_i="24381" txt_f="24383">42</offsets></xref><offsets xml_i="33478" xml_f="33705" txt_i="24383" txt_f="24610">]. Depending on whether the clinician uses early enteral or parenteral nutrition, the flux of lactate may be affected differently in critically ill patients, and therefore our results in healthy subjects may not apply directly.</offsets></p></sec><sec sec-type="conclusions"><title><offsets xml_i="33750" xml_f="33761" txt_i="24612" txt_f="24623">Conclusions</offsets></title><p><offsets xml_i="33772" xml_f="34629" txt_i="24624" txt_f="25481">These observations indicate that, in healthy humans, LPS administration leads to consistent increases in plasma lactate concentrations secondary to a stimulation of lactate production. However, the microdialysis data suggest that - provided that there was no increase in muscle blood flow - skeletal muscle was not a major contributor to LPS-induced lactate production. Further studies will be required to further evaluate which tissues are involved in LPS-induced lactate production, but immune cells and the reticulo-endothelial systems are obvious candidates as they are prime targets of cytokines secreted in response to LPS. Endotoxin administration increased fasting glucose concentration and endogenous glucose production, but this effect does not appear to be directly related to a stimulation of glucose production by enhanced lactate availability.</offsets></p></sec><sec><title><offsets xml_i="34651" xml_f="34663" txt_i="25483" txt_f="25495">Key messages</offsets></title><p><offsets xml_i="34674" xml_f="34750" txt_i="25496" txt_f="25572">• Endotoxin administration leads to increased plasma lactate concentrations.</offsets></p><p><offsets xml_i="34757" xml_f="34835" txt_i="25573" txt_f="25651">• Resting energy expenditure increased significantly in response to endotoxin.</offsets></p><p><offsets xml_i="34842" xml_f="34919" txt_i="25652" txt_f="25729">• This increase is caused by a stimulation of glucose and lactate production.</offsets></p><p><offsets xml_i="34926" xml_f="34991" txt_i="25730" txt_f="25795">• This increased lactate production does not occur in the muscle.</offsets></p></sec><sec><title><offsets xml_i="35013" xml_f="35026" txt_i="25797" txt_f="25810">Abbreviations</offsets></title><p><offsets xml_i="35037" xml_f="35244" txt_i="25811" txt_f="26018">ACTH: adrenocorticotropine; ANOVA: analysis of variance; BMI: body mass index; CRP: C-reactive protein; FFA: free fatty acid; IL-6: interleukin 6; LPS: lipopolysaccharide; TNF-α: tumor necrosis factor-alpha.</offsets></p></sec><sec><title><offsets xml_i="35266" xml_f="35285" txt_i="26020" txt_f="26039">Competing interests</offsets></title><p><offsets xml_i="35296" xml_f="35354" txt_i="26040" txt_f="26098">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="35376" xml_f="35398" txt_i="26100" txt_f="26122">Authors' contributions</offsets></title><p><offsets xml_i="35409" xml_f="35798" txt_i="26123" txt_f="26512">RLC, LT, J-PR, and MMB helped to conceive the study and draft and revise the manuscript. M-CC helped to conceive the study, conduct the trial, and acquire and analyze the data. AM helped to conduct the trial, acquire and analyze the data. BM helped to conduct the trial, acquire and analyze the data, and draft and revise the manuscript. All authors read and approved the final manuscript.</offsets></p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Wilmore</surname><given-names>DW</given-names></name><article-title>Alterations in protein, carbohydrate, and fat metabolism in injured and septic patients</article-title><source>J Am Coll Nutr</source><year>1983</year><volume>2</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">6886243</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Wilmore</surname><given-names>DW</given-names></name><article-title>Metabolic response to severe surgical illness: overview</article-title><source>World J Surg</source><year>2000</year><volume>24</volume><fpage>705</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1007/s002689910113</pub-id><pub-id pub-id-type="pmid">10773123</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Karl</surname><given-names>IE</given-names></name><article-title>The pathophysiology and treatment of sepsis</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>138</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1056/NEJMra021333</pub-id><pub-id pub-id-type="pmid">12519925</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Gutierrez</surname><given-names>G</given-names></name><name><surname>Wulf</surname><given-names>ME</given-names></name><article-title>Lactic acidosis in sepsis: a commentary</article-title><source>Intensive Care Med</source><year>1996</year><volume>22</volume><fpage>6</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/BF01728325</pub-id><pub-id pub-id-type="pmid">8857432</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>James</surname><given-names>JH</given-names></name><name><surname>Luchette</surname><given-names>FA</given-names></name><name><surname>McCarter</surname><given-names>FD</given-names></name><name><surname>Fischer</surname><given-names>JE</given-names></name><article-title>Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis</article-title><source>Lancet</source><year>1999</year><volume>354</volume><fpage>505</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)91132-1</pub-id><pub-id pub-id-type="pmid">10465191</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Mizock</surname><given-names>BA</given-names></name><name><surname>Falk</surname><given-names>JL</given-names></name><article-title>Lactic acidosis in critical illness</article-title><source>Crit Care Med</source><year>1992</year><volume>20</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/00003246-199201000-00020</pub-id><pub-id pub-id-type="pmid">1309494</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Levraut</surname><given-names>J</given-names></name><name><surname>Ciebiera</surname><given-names>JP</given-names></name><name><surname>Chave</surname><given-names>S</given-names></name><name><surname>Rabary</surname><given-names>O</given-names></name><name><surname>Jambou</surname><given-names>P</given-names></name><name><surname>Carles</surname><given-names>M</given-names></name><name><surname>Grimaud</surname><given-names>D</given-names></name><article-title>Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>157</volume><fpage>1021</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">9563714</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Levy</surname><given-names>B</given-names></name><article-title>Lactate and shock state: the metabolic view</article-title><source>Curr Opin Crit Care</source><year>2006</year><volume>12</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1097/01.ccx.0000235208.77450.15</pub-id><pub-id pub-id-type="pmid">16810041</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Arnold</surname><given-names>RC</given-names></name><name><surname>Shapiro</surname><given-names>NI</given-names></name><name><surname>Jones</surname><given-names>AE</given-names></name><name><surname>Schorr</surname><given-names>C</given-names></name><name><surname>Pope</surname><given-names>J</given-names></name><name><surname>Casner</surname><given-names>E</given-names></name><name><surname>Parrillo</surname><given-names>JE</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Trzeciak</surname><given-names>S</given-names></name><article-title>Multi-center study of early lactate clearance as a determinant of survival in patients with presumed sepsis</article-title><source>Shock</source><year>2008</year><volume>32</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">19533847</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Nguyen</surname><given-names>HB</given-names></name><name><surname>Loomba</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Jacobsen</surname><given-names>G</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Otero</surname><given-names>RM</given-names></name><name><surname>Suarez</surname><given-names>A</given-names></name><name><surname>Parekh</surname><given-names>H</given-names></name><name><surname>Jaehne</surname><given-names>A</given-names></name><name><surname>Rivers</surname><given-names>EP</given-names></name><article-title>Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock</article-title><source>J Inflamm (Lond)</source><year>2010</year><volume>7</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1476-9255-7-6</pub-id><pub-id pub-id-type="pmid">20181046</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Leverve</surname><given-names>XM</given-names></name><article-title>Energy metabolism in critically ill patients: lactate is a major oxidizable substrate</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>1999</year><volume>2</volume><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1097/00075197-199903000-00013</pub-id><pub-id pub-id-type="pmid">10453349</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Leverve</surname><given-names>XM</given-names></name><article-title>Lactic acidosis. A new insight?</article-title><source>Minerva Anestesiol</source><year>1999</year><volume>65</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">10389393</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Van Deventer</surname><given-names>SJ</given-names></name><name><surname>Buller</surname><given-names>HR</given-names></name><name><surname>ten Cate</surname><given-names>JW</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Sturk</surname><given-names>A</given-names></name><article-title>Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways</article-title><source>Blood</source><year>1990</year><volume>76</volume><fpage>2520</fpage><lpage>2526</lpage><pub-id pub-id-type="pmid">2124934</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>Lowry</surname><given-names>SF</given-names></name><article-title>Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?</article-title><source>Shock</source><year>1995</year><volume>3</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">7850574</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Soop</surname><given-names>M</given-names></name><name><surname>Duxbury</surname><given-names>H</given-names></name><name><surname>Agwunobi</surname><given-names>AO</given-names></name><name><surname>Gibson</surname><given-names>JM</given-names></name><name><surname>Hopkins</surname><given-names>SJ</given-names></name><name><surname>Childs</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>RG</given-names></name><name><surname>Maycock</surname><given-names>P</given-names></name><name><surname>Little</surname><given-names>RA</given-names></name><name><surname>Carlson</surname><given-names>GL</given-names></name><article-title>Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans</article-title><source>Am J Physiol Endocrinol Metab</source><year>2002</year><volume>282</volume><fpage>E1276</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">12006357</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Vesali</surname><given-names>RF</given-names></name><name><surname>Klaude</surname><given-names>M</given-names></name><name><surname>Rooyackers</surname><given-names>O</given-names></name><name><surname>Wernerman</surname><given-names>J</given-names></name><article-title>Amino acid metabolism in leg muscle after an endotoxin injection in healthy volunteers</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>288</volume><fpage>E360</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00248.2004</pub-id><pub-id pub-id-type="pmid">15367399</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Bloesch</surname><given-names>D</given-names></name><name><surname>Keller</surname><given-names>U</given-names></name><name><surname>Spinas</surname><given-names>GA</given-names></name><name><surname>Kury</surname><given-names>D</given-names></name><name><surname>Girard</surname><given-names>J</given-names></name><name><surname>Stauffacher</surname><given-names>W</given-names></name><article-title>Effects of endotoxin on leucine and glucose kinetics in man: contribution of prostaglandin E2 assessed by a cyclooxygenase inhibitor</article-title><source>J Clin Endocrinol Metab</source><year>1993</year><volume>77</volume><fpage>1156</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1210/jc.77.5.1156</pub-id><pub-id pub-id-type="pmid">8077306</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Jallut</surname><given-names>D</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><name><surname>Kohut</surname><given-names>M</given-names></name><name><surname>Bloesch</surname><given-names>D</given-names></name><name><surname>Munger</surname><given-names>R</given-names></name><name><surname>Schutz</surname><given-names>Y</given-names></name><name><surname>Chiolero</surname><given-names>R</given-names></name><name><surname>Felber J</surname><given-names>P</given-names></name><name><surname>Livio</surname><given-names>JJ</given-names></name><name><surname>Jequier</surname><given-names>E</given-names></name><article-title>Energy balance in elderly patients after surgery for a femoral neck fracture</article-title><source>JPEN J Parenter Enteral Nutr</source><year>1990</year><volume>14</volume><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1177/0148607190014006563</pub-id><pub-id pub-id-type="pmid">2273529</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Livesey</surname><given-names>G</given-names></name><name><surname>Elia</surname><given-names>M</given-names></name><article-title>Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels</article-title><source>Am J Clin Nutr</source><year>1988</year><volume>47</volume><fpage>608</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">3281434</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Revelly</surname><given-names>JP</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Bollmann</surname><given-names>M</given-names></name><name><surname>Cayeux</surname><given-names>MC</given-names></name><name><surname>Berger</surname><given-names>MM</given-names></name><name><surname>Chiolero</surname><given-names>RL</given-names></name><article-title>Lactate and glucose metabolism in severe sepsis and cardiogenic shock</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>2235</fpage><lpage>2240</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000181525.99295.8F</pub-id><pub-id pub-id-type="pmid">16215376</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Connor</surname><given-names>H</given-names></name><name><surname>Woods</surname><given-names>HF</given-names></name><name><surname>Ledingham</surname><given-names>JG</given-names></name><name><surname>Murray</surname><given-names>JD</given-names></name><article-title>A model of L(+)-lactate metabolism in normal man</article-title><source>Ann Nutr Metab</source><year>1982</year><volume>26</volume><fpage>254</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1159/000176571</pub-id><pub-id pub-id-type="pmid">7137947</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Farnebo</surname><given-names>LO</given-names></name><name><surname>Hallman</surname><given-names>H</given-names></name><name><surname>Hamberger</surname><given-names>B</given-names></name><name><surname>Jonsson</surname><given-names>G</given-names></name><article-title>Catecholamines and hemorrhagic shock in awake and anesthetized rats</article-title><source>Circ Shock</source><year>1979</year><volume>6</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">455594</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Pelletier</surname><given-names>O</given-names></name><name><surname>Arratoon</surname><given-names>C</given-names></name><article-title>Precision of glucose measurements in control sera by isotope dilution/mass spectrometry: proposed definitive method compared with a reference method</article-title><source>Clin Chem</source><year>1987</year><volume>33</volume><fpage>1397</fpage><lpage>1402</lpage><pub-id pub-id-type="pmid">3301068</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Novel-Chate</surname><given-names>V</given-names></name><name><surname>Rey</surname><given-names>V</given-names></name><name><surname>Chiolero</surname><given-names>R</given-names></name><name><surname>Schneiter</surname><given-names>P</given-names></name><name><surname>Leverve</surname><given-names>X</given-names></name><name><surname>Jequier</surname><given-names>E</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><article-title>Role of Na+-K+-ATPase in insulin-induced lactate release by skeletal muscle</article-title><source>Am J Physiol Endocrinol Metab</source><year>2001</year><volume>280</volume><fpage>E296</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">11158933</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>DeBodo</surname><given-names>R</given-names></name><name><surname>Steele</surname><given-names>R</given-names></name><name><surname>Altszuler</surname><given-names>N</given-names></name><name><surname>Dunn</surname><given-names>A</given-names></name><name><surname>Bishop</surname><given-names>J</given-names></name><article-title>On the hormonal regulation of carbohydrate metabolism : studies with <sup>14</sup>C-glucose</article-title><source>Recent Prog Horm Res</source><year>1963</year><volume>19</volume><fpage>445</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">14284029</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Livesey</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>PD</given-names></name><name><surname>Dainty</surname><given-names>JR</given-names></name><name><surname>Brown</surname><given-names>JC</given-names></name><name><surname>Faulks</surname><given-names>RM</given-names></name><name><surname>Roe</surname><given-names>MA</given-names></name><name><surname>Newman</surname><given-names>TA</given-names></name><name><surname>Eagles</surname><given-names>J</given-names></name><name><surname>Mellon</surname><given-names>FA</given-names></name><name><surname>Greenwood</surname><given-names>RH</given-names></name><article-title>Simultaneous time-varying systemic appearance of oral and hepatic glucose in adults monitored with stable isotopes</article-title><source>Am J Physiol</source><year>1998</year><volume>275</volume><fpage>E717</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">9755093</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Chiolero</surname><given-names>R</given-names></name><name><surname>Mavrocordatos</surname><given-names>P</given-names></name><name><surname>Burnier</surname><given-names>P</given-names></name><name><surname>Cayeux</surname><given-names>MC</given-names></name><name><surname>Schindler</surname><given-names>C</given-names></name><name><surname>Jequier</surname><given-names>E</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><article-title>Effects of infused sodium acetate, sodium lactate, and sodium beta-hydroxybutyrate on energy expenditure and substrate oxidation rates in lean humans</article-title><source>Am J Clin Nutr</source><year>1993</year><volume>58</volume><fpage>608</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">8237864</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Binnert</surname><given-names>C</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><article-title>Microdialysis in the intensive care unit: a novel tool for clinical investigation or monitoring?</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2002</year><volume>5</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1097/00075197-200203000-00011</pub-id><pub-id pub-id-type="pmid">11844986</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Paquot</surname><given-names>N</given-names></name><name><surname>Schneiter</surname><given-names>P</given-names></name><name><surname>Cayeux</surname><given-names>MC</given-names></name><name><surname>Chiolero</surname><given-names>R</given-names></name><name><surname>Temler</surname><given-names>E</given-names></name><name><surname>Jequier</surname><given-names>E</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><article-title>Effects of infused sodium lactate on glucose and energy metabolism in healthy humans</article-title><source>Diabete Metab</source><year>1995</year><volume>21</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">8586151</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Michaeli</surname><given-names>B</given-names></name><name><surname>Berger</surname><given-names>MM</given-names></name><name><surname>Revelly</surname><given-names>JP</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><name><surname>Chiolero</surname><given-names>R</given-names></name><article-title>Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers</article-title><source>Clin Nutr</source><year>2007</year><volume>26</volume><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2006.06.001</pub-id><pub-id pub-id-type="pmid">17055120</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Chiolero</surname><given-names>R</given-names></name><name><surname>Bollman</surname><given-names>M</given-names></name><name><surname>Revelly</surname><given-names>JP</given-names></name><name><surname>Berger</surname><given-names>M</given-names></name><name><surname>Cayeux</surname><given-names>C</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><article-title>Assessment of adipose tissue metabolism by means of subcutaneous microdialysis in patients with sepsis or circulatory failure</article-title><source>Clin Physiol Funct Imaging</source><year>2003</year><volume>23</volume><fpage>286</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1046/j.1475-097X.2003.00512.x</pub-id><pub-id pub-id-type="pmid">12950327</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Nevière</surname><given-names>R</given-names></name><name><surname>Mathieu</surname><given-names>D</given-names></name><name><surname>Chagnon</surname><given-names>JL</given-names></name><name><surname>Lebleu</surname><given-names>N</given-names></name><name><surname>Millien</surname><given-names>JP</given-names></name><name><surname>Wattel</surname><given-names>F</given-names></name><article-title>Skeletal muscle microvascular blood flow and oxygen transport in patients with severe sepsis</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>153</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">8542115</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Jepson</surname><given-names>MM</given-names></name><name><surname>Cox</surname><given-names>M</given-names></name><name><surname>Bates</surname><given-names>PC</given-names></name><name><surname>Rothwell</surname><given-names>NJ</given-names></name><name><surname>Stock</surname><given-names>MJ</given-names></name><name><surname>Cady</surname><given-names>EB</given-names></name><name><surname>Millward</surname><given-names>DJ</given-names></name><article-title>Regional blood flow and skeletal muscle energy status in endotoxemic rats</article-title><source>Am J Physiol</source><year>1987</year><volume>252</volume><fpage>E581</fpage><lpage>E587</lpage><pub-id pub-id-type="pmid">3555111</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Fong</surname><given-names>YM</given-names></name><name><surname>Marano</surname><given-names>MA</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Calvano</surname><given-names>SE</given-names></name><name><surname>Kenney</surname><given-names>JS</given-names></name><name><surname>Allison</surname><given-names>AC</given-names></name><name><surname>Cerami</surname><given-names>A</given-names></name><name><surname>Shires</surname><given-names>GT</given-names></name><name><surname>Lowry</surname><given-names>SF</given-names></name><article-title>The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans</article-title><source>J Clin Invest</source><year>1990</year><volume>85</volume><fpage>1896</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.1172/JCI114651</pub-id><pub-id pub-id-type="pmid">2347917</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Chiolero</surname><given-names>R</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><name><surname>Gillet</surname><given-names>M</given-names></name><name><surname>Revelly</surname><given-names>JP</given-names></name><name><surname>Roth</surname><given-names>H</given-names></name><name><surname>Cayeux</surname><given-names>C</given-names></name><name><surname>Schneiter</surname><given-names>P</given-names></name><name><surname>Leverve</surname><given-names>X</given-names></name><article-title>Effect of major hepatectomy on glucose and lactate metabolism</article-title><source>Ann Surg</source><year>1999</year><volume>229</volume><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1097/00000658-199904000-00009</pub-id><pub-id pub-id-type="pmid">10203083</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Chiolero</surname><given-names>RL</given-names></name><name><surname>Revelly</surname><given-names>JP</given-names></name><name><surname>Leverve</surname><given-names>X</given-names></name><name><surname>Gersbach</surname><given-names>P</given-names></name><name><surname>Cayeux</surname><given-names>MC</given-names></name><name><surname>Berger</surname><given-names>MM</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name><article-title>Effects of cardiogenic shock on lactate and glucose metabolism after heart surgery</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>3784</fpage><lpage>3791</lpage><pub-id pub-id-type="doi">10.1097/00003246-200012000-00002</pub-id><pub-id pub-id-type="pmid">11153615</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Mustafa</surname><given-names>I</given-names></name><name><surname>Leverve</surname><given-names>XM</given-names></name><article-title>Metabolic and hemodynamic effects of hypertonic solutions: sodium-lactate versus sodium chloride infusion in postoperative patients</article-title><source>Shock</source><year>2002</year><volume>18</volume><fpage>306</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1097/00024382-200210000-00003</pub-id><pub-id pub-id-type="pmid">12392272</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Jenssen</surname><given-names>T</given-names></name><name><surname>Nurjhan</surname><given-names>N</given-names></name><name><surname>Consoli</surname><given-names>A</given-names></name><name><surname>Gerich</surname><given-names>JE</given-names></name><article-title>Dose-response effects of lactate infusions on gluconeogenesis from lactate in normal man</article-title><source>Eur J Clin Invest</source><year>1993</year><volume>23</volume><fpage>448</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.1993.tb00789.x</pub-id><pub-id pub-id-type="pmid">8404995</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Tappy</surname><given-names>L</given-names></name><name><surname>Cayeux</surname><given-names>MC</given-names></name><name><surname>Schneiter</surname><given-names>P</given-names></name><name><surname>Schindler</surname><given-names>C</given-names></name><name><surname>Temler</surname><given-names>E</given-names></name><name><surname>Jequier</surname><given-names>E</given-names></name><name><surname>Chiolero</surname><given-names>R</given-names></name><article-title>Effects of lactate on glucose metabolism in healthy subjects and in severely injured hyperglycemic patients</article-title><source>Am J Physiol</source><year>1995</year><volume>268</volume><fpage>E630</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">7733261</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>MC</given-names></name><name><surname>Connolly</surname><given-names>CC</given-names></name><name><surname>Cherrington</surname><given-names>AD</given-names></name><article-title>Autoregulation of hepatic glucose production</article-title><source>Eur J Endocrinol</source><year>1998</year><volume>138</volume><fpage>240</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1530/eje.0.1380240</pub-id><pub-id pub-id-type="pmid">9539293</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Awad</surname><given-names>S</given-names></name><name><surname>Stephenson</surname><given-names>MC</given-names></name><name><surname>Placidi</surname><given-names>E</given-names></name><name><surname>Marciani</surname><given-names>L</given-names></name><name><surname>Constantin-Teodosiu</surname><given-names>D</given-names></name><name><surname>Gowland</surname><given-names>PA</given-names></name><name><surname>Spiller</surname><given-names>RC</given-names></name><name><surname>Fearon</surname><given-names>KC</given-names></name><name><surname>Morris</surname><given-names>PG</given-names></name><name><surname>Macdonald</surname><given-names>IA</given-names></name><name><surname>Lobo</surname><given-names>DN</given-names></name><article-title>The effects of fasting and refeeding with a 'metabolic preconditioning' drink on substrate reserves and mononuclear cell mitochondrial function</article-title><source>Clin Nutr</source><year>2010</year><volume>29</volume><fpage>538</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2010.01.009</pub-id><pub-id pub-id-type="pmid">20138692</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Fong</surname><given-names>YM</given-names></name><name><surname>Marano</surname><given-names>MA</given-names></name><name><surname>Braber</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name><name><surname>Bushman</surname><given-names>ED</given-names></name><name><surname>Coyle</surname><given-names>SM</given-names></name><name><surname>Shires</surname><given-names>GT</given-names></name><name><surname>Lowry</surname><given-names>SF</given-names></name><article-title>Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans</article-title><source>Ann Surg</source><year>1989</year><volume>210</volume><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1097/00000658-198910000-00005</pub-id><pub-id pub-id-type="pmid">2508583</pub-id></mixed-citation></ref></ref-list></back></article>